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Abstract 
Abstract word count: 240 
Background: Both single and bilateral lung transplantation (LT) are recognized options for 
patients with end-stage chronic obstructive pulmonary disease (COPD); however, the choice 
of procedure leading to longer survival remains unclear. We aimed to compare survival 
following both procedures by analysing the data from the registry of the International Society 
for Heart and Lung Transplantation.  
Methods: Data for 9883 COPD patients who underwent bilateral (35.7%) or single (64.3%) 
LT between 1987 and 2006 worldwide were analysed. Analysis of covariance, propensity-
score risk adjustment and propensity-based matching were used to take into account selection 
bias. 
Findings: Median survival following LT for COPD was 5.0 years (95% CI 4.81–5.22) and 
improved over time. The proportion of patients undergoing bilateral LT increased, from 
20.4% in 1993 to 56.2% in 2006. Median survival time following bilateral LT was 
significantly longer than that following single LT: 6.41 years (6.02–6.88) versus 4.59 (4.41–
4.76), p < 0.0001; however, pretransplant characteristics of patients undergoing single and 
bilateral LT differed markedly. Whatever the method used to adjust for baseline differences, 
bilateral LT was associated with longer survival than single LT, the hazard ratio ranging from 
0.83 (0.78–0.92) for analysis of covariance to 0.89 (0.80–0.97) for propensity-based 
matching. The benefit of bilateral LT over single LT seemed low in patients older than 60 
years.   
Interpretation: Bilateral LT appears to lead to longer survival than single LT in patients with 
COPD, especially those younger than 60 years.  
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Introduction 
Lung transplantation (LT) is the ultimate therapy available for selected patients with 
end-stage lung diseases.1, 2 Among such diseases, chronic obstructive pulmonary disease 
(COPD) represents one of the major indications for LT. According to the 2006 report of the 
International Registry of the International Society for Heart and Lung Transplantation 
(ISHLT), 46% of LTs were performed for COPD from January 1995 to June 2005.3  
Patients with advanced COPD are now offered single LT (SLT) or bilateral LT (BLT). 
The latter was first developed at the end of the 1980s as an en-bloc procedure.4 The technique 
was subsequently modified to a bilateral sequential technique. SLT was initially considered a 
contraindication for COPD for anatomic and physiologic reasons, but after the demonstration 
in 1988 of the feasibility and immediate good tolerance of SLT in this setting,5, 6 confirmed by 
satisfying medium-term results,7, 8 the procedure has become the most frequent type of LT 
performed in these patients. However, the choice of SLT or BLT for COPD patients is still a 
matter of debate.9-12 In comparison with BLT, SLT is an easier procedure and can be used for 
patients with advanced disease; it also potentially allows for economy of organs because the 
lungs from a single donor can theoretically be implanted in two patients. The main drawback 
of SLT is the potential occurrence of complications -- infection, hemoptysis, pneumothorax 
and hyperinflation -- affecting the native lung.13, 14  
Both SLT and BLT yield a similar benefit in terms of exercise capacity,15, 16 but a 
survival advantage of BLT over SLT has recently been suggested by results of several studies, 
both from single centers,17, 18 and from the ISHLT registry.19 This survival advantage has 
probably been taken into account by many transplant physicians and might explain why many 
centers now favour the use of BLT for COPD. However, in the absence of a randomized 
controlled trial comparing SLT and BLT in patients with COPD, a comparison of survival 
after both operations is difficult. Current evidence comes from cohort studies prone to 
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confounding factors by the indication for the procedure: study outcomes are affected by the 
differing characteristics of patients undergoing SLT or BLT, apart from those related to the 
interventions being assessed.20 For instance, patients undergoing BLT are in general younger 
than those undergoing SLT, which potentially leads to a bias, since age is a well-known 
prognostic factor of survival after LT. Even if a survival benefit with BLT has been reported 
by authors who analyzed the results of both procedures after stratifying patients by age,19 
other confounding factors may still bias the comparison of survival data.  
We aimed to compare survival rates following BLT and SLT for COPD patients by 
using several techniques that account for confounding factors: analysis of covariance, 
propensity-score risk adjustment and propensity-based matching. 
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Methods 
 This study report follows the STROBE statement.21 
Patients  
We used information from the ISHLT registry (www.ishlt.org) as of March 2007. The 
registry contains data on 21,265 lung recipients from 210 centers around the world since its 
inception in 1987.22 All patients who underwent LT between 1987 and 2006 in the 
participating centers were eligible for the study provided that 1) they underwent cadaveric 
SLT or BLT for COPD (including COPD related to alpha-1 anti-trypsin deficiency);23 2) the 
date of LT was known; 3) the date of last follow-up was known; and 4) the vital status at last 
follow-up was known.  
 
Selection of variables for survival analysis 
Data on 240 variables related to characteristics of patients at the time of 
transplantation were collected by the ISHLT registry. We excluded variables for which data 
were sparse or those that described clinically uncommon or rare characteristics. Several 
variables were calculated from available variables (i.e. gender mismatch). Table 1 indicates 
the variables included in the analyses.   
 
Handling of missing data 
For variables involved in the analysis of covariance and propensity-score 
development, missing data were imputed by the multiple-imputations-by-chained equation, 
which resulted in 5 imputed datasets.24 We independently analysed the 5 copies of the data. 
We averaged estimates of the variables to give a single mean estimate and adjusted standard 
errors according to Rubin’s rules.24 The steps of the imputation procedure are given in the 
online data supplement (ODS).  
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Statistical methods 
We used 3 methods to adjust for confounding factors: analysis of covariance, 
propensity-score risk adjustment and propensity-score matching. 
 
Analysis of covariance 
Analysis of covariance refers here to a standard statistical approach that produces 
estimates of treatment effects adjusted for background characteristics (covariates), which are 
included explicitly in Cox proportional-hazard regression models. We used purposeful 
selection of covariates as described by Hosmer and Lemeshow to select the multivariable 
model.25 The first step was the inclusion of all variables significant in the bivariate analysis at 
the 20% level as well as all variables known to be clinically relevant.26 The second step was 
to remove, one by one, variables that did not significantly contribute to the multivariable 
model on the basis of the p value of the Wald test and on the change in the coefficient of the 
remaining variables. The scale of the continuous covariates was assessed by residual 
analysis.25, 27 Only first-order interactions with surgical procedure were considered.  
Propensity-score adjustment and matching 
The propensity score is the probability of undergoing BLT instead of SLT for a patient 
with specific pre-treatment characteristics.28, 29 Within propensity-score strata, covariates in 
both groups tend to be similarly distributed. We computed the propensity score by using 
logistic regression, the dependent variable being surgical procedure and the covariates being 
all variables listed in Table 1. Continuous variables were entered into the model as second-
order polynomials. The success of the propensity-score modelling was judged by whether 
balance on baseline characteristics was achieved between the BLT and SLT groups within 
deciles of propensity score or after propensity-score matching. 
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We used covariate adjustment with the propensity score and propensity-based 
matching to produce adjusted estimates of the effect of BLT.30 Covariate adjustment with the 
propensity score involved use of a Cox proportional-hazard regression model to regress 
survival following LT on the propensity score (on the linear predictor scale) and the variable 
denoting surgical procedure. We used a 1:1 matching algorithm without replacement to match 
subjects with use of callipers defined to have a maximum width of 0.25 SDs of the logit of the 
estimated propensity score. Marginal Cox models, accounting for correlation within matched 
pairs, were used to compare adjusted survival between patients undergoing SLT and those 
undergoing BLT.  
Interpretation of results 
All these models yielded the effect of BLT on survival as a hazard ratio for death, with 
the SLT group being the reference. To compute a more meaningful measure of the survival 
effect of BLT, we computed the difference in terms of survival rate at 5 years using the 
following formula: S(t;BLT) = S(t;SLT)(HR) . 
Test of the Cox proportional-hazard assumption 
We used several statistical methods to assess whether the effect of surgical procedure 
was constant over time (proportional-hazard assumption), including residual plots as 
described by Grambsch and Therneau31 and fitting of  Cox models in which the post-
transplant period is split into 3 periods: the first year after transplantation, between 1 and 5 
years after transplantation, and more than 5 years after transplantation.  
 
 
Statistical software 
All analyses involved the use of R 2.5 for Windows XP. Propensity-score matching 
involved use of the ‘Matching’ package for R.  
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Role of the funding source 
There was no funding source in relation with this study. The authors had full access to 
all the data in the study and had the final responsibility for the decision to submit for 
publication. 
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Results 
The ISHLT database included data for 9952 COPD patients undergoing LT between 
1987 and 2007. Survival times were not available for 69 patients, which left data for 9883 
patients for analysis. Of these patients, 1963 (19.9%) had alpha-1 antitrypsin deficiency as a 
risk factor for COPD. 
The mean follow-up was 6.72 years. Median survival following LT was 5.0 years 
(95% CI 4.81-5.22). Survival rates at 1, 3 and 5 years were 80.6% (79.8%–81.4%), 63.8% 
(62.8%–64.8%) and 50.0% (48.8%–51.2%), respectively. Survival following LT improved in 
more recent years, median survival being 4.53 years (4.31–4.81) before 1998 and 5.3 years 
(5.01-5.50) from 1998 onward (p<0.001).  
 Among the 9883 COPD patients undergoing LT, 6358 patients underwent SLT 
(64.3%) and 3525 (35.7%) BLT. Figure 1 depicts the evolution of these proportions over 
time. Rates of BLT changed from 20.4% in 1993 to 56.2% in 2006. The proportion of BLT 
performed decreased with increasing age: 49.7% of patients younger than 50 years underwent 
BLT as compared with 23.9% older than 60 years. The rate of BLT differed markedly 
according to alpha-1 antitrypsin deficiency status: 50.0% for patients with the deficiency as 
compared with 32.1% without the deficiency (p<0.001).  
Median survival time following BLT was significantly higher than that following 
SLT: 6.41 years (6.02-6.88) versus 4.59 years (4.41-4.76; p < 0.0001) (Figure 2A). Similar 
results were observed for patients undergoing LT only in recent years (from 1998 onward) 
6.72 years (5.88-7.2) vs. 4.90 (4.68-5.29), p<0.001. 
The characteristics of patients are in Table 2 and show some imbalance by procedure 
performed. As expected, graft ischemic time was significantly longer for patients undergoing 
BLT than SLT [5.4 (SD 1.7) vs. 3.8 (1.4) hours; p<0.0001].  
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Analysis of covariance 
In an unadjusted Cox analysis, the hazard ratio for BLT as compared with SLT was 
0.76 (95% CI 0.70–0.83), which indicates a protective effect of BLT on mortality. Purposeful 
selection of the covariates led to a multivariate model including the following variables: 
surgical procedure, age at transplantation, New York Heart Association functional class, body 
mass index, ventilator requirement, donor age, donor body mass index, donor with diabetes, 
number of human leucocyte antigen mismatches, cytomegalovirus (CMV) mismatch (i.e. 
donor CMV+ and recipient CMV-) and year of transplantation. Residual plot results 
supported a linear relation between all continuous covariates and the log hazard of death. No 
significant interaction was retained in the final model; in particular, interaction  between age 
at transplantation and type of procedure was not significant (p=0.25). According to this 
model, the adjusted hazard ratio for BLT was 0.83 (0.78–0.92).  
Figure 3 shows the survival effect of LT according to recipient age (quartiles of 
distribution). For this analysis, a proportional-hazard model including the variables described 
above was fitted for each quartile of age distribution. BLT was associated with better adjusted 
survival up to 60 years than was SLT. After 60 years, the hazard ratio for BLT was no longer 
statistically significant.   
 
Propensity score 
The propensity score included all variables pertaining to donors, patients and surgical 
procedure characteristics. The propensity score ranged from 0.03 to 0.90 on the probability 
scale. The distribution of variables was well balanced within deciles of the propensity score. 
Table 3 shows the balance within deciles of the propensity score for selected covariates. A 
multivariate model adjusted for propensity-score deciles gave an adjusted hazard ratio for 
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transplant procedure of 0.84 (95% CI 0.79–0.90). The ratio was 0.86 (0.81–0.93) when the 
covariates of the multivariate model described above were added to the model.  
We successfully matched 3024 patients undergoing SLT with 3024 patients 
undergoing BLT on the basis of propensity score. Table 4 gives the main characteristics of 
these patients according to procedure, showing a good balance of baseline characteristics 
between the 2 groups. Figure 2B displays the survival of the 6048 patients matched on the 
propensity score, according to the transplantation procedure. In a marginal Cox models, 
accounting for correlation within matched pairs, BLT was associated with a significant 
reduction in of the instantaneous risk of death, with a hazard ratio of 0.89 (95% CI 0.80–
0.97). Figure 4 summarizes the hazard ratios for death according to surgical procedure by the 
different statistical methods. 
 
Proportional-hazards assumption 
Despite no formal violation of the Cox proportional hazard assumption, results of 
residuals plots suggested that the beneficial effect of BLT begins about one year after LT, 
both procedures being approximately equivalent in terms of survival during the first year after 
the procedure. This finding is confirmed by results of a Cox analysis in which time after 
transplantation was divided into three parts: the first year after transplantation, between 1 and 
5 years after transplantation, and more than 5 years after transplantation. This analysis 
included the covariates of the multivariate model described above. The adjusted hazard ratios 
for BLT as compared with SLT for the three post-transplantation periods were 1.05 (95% CI 
0.95–1.17), 0.77 (0.70–0.86) and 0.72 (0.62–0.83), respectively.  
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Survival rates at 5 years 
The unadjusted difference in 5-year survival rate for patients undergoing LT from 
1998 onward was 7.2%. As shown above, the adjusted hazard ratio for BLT ranged from 0.83 
to 0.89 depending on the statistical method. Taking into account a 5-year survival rate of 
49.3% for patients undergoing SLT, BLT was associated with an adjusted difference in better 
5-year survival ranging from 4.0% to 6.3%.  
Sensitivity analyses 
 We ran several sensitivity analyses to test the robustness of our findings. The same 
analyses were performed for patients undergoing LT from 1998 onward (n=5768). This 
analysis yielded results very similar to those for the whole sample, the adjusted hazard ratio 
for BLT being 0.87 (95% CI 0.81–0.95) with analysis of covariance. We also restricted an 
analysis to patients undergoing LT in the United States (n=5873): the adjusted hazard ratio for 
BLT with analysis of covariance was 0.86 (0.78–0.95).  
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Discussion 
A thorough analysis of the ISHLT registry suggests that (1) BLT is associated with 
longer survival than SLT among COPD patients, whatever the statistical method used to 
account for confounding factors; (2) BLT seems to yield more benefit for patients younger 
than 60 years; (3) the benefit of BLT over SLT becomes apparent in the second year after LT.  
The optimal transplant procedure for COPD is still a matter of debate.12 However, in 
recent years, the publication of results of several studies suggesting a survival advantage of 
BLT over SLT has led to a progressive shift in the choice of procedure. BLT now represents 
most LT procedures performed for COPD (including patients with alpha-1 antitrypsin 
deficiency). Cassivi et al reported their experience with 306 emphysema patients undergoing 
SLT (28.9%) or BLT (71.1%) from 1988 to 2000.17 Despite similar in-hospital mortality 
between the groups, patients undergoing BLT had higher 5-year survival than those 
undergoing SLT (66.7% vs. 44.9%, p<0.001). However, patients undergoing BLT were 
younger and more frequently had alpha-1 antitrypsin deficiency. More recently, Gunes et al 
reported their experience with 173 COPD patients receiving heart-lung transplantation (n=8), 
SLT (n=99) or BLT (n=66) from 1999 to 2003.18 Patients undergoing BLT had higher 5-year 
survival than those undergoing SLT (81.0% vs. 47.0%, p<0.001). In this study, baseline 
characteristics of SLT and BLT were similar. Meyer et al analysed ISHLT registry data for all 
COPD patients (those with alpha-1 antitrypsin deficiency were excluded) who underwent 
cadaveric SLT or BLT from 1991 to 1997 and attempted to take into account possible 
confounding factors, including age.19 Patients undergoing BLT had higher 5-year survival 
than those undergoing SLT (68.2% vs. 43.6%, p<0.001) and were younger (50.5 vs. 54.8 
years). In multivariate analysis, adjusting for recipient age, SLT patients aged 40 to 57 years 
had higher mortality than BLT patients.  
Our study has several strengths, compared to previously published investigations.  
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First, we included all patients who underwent LT up to the year 2007. Since the survival  of 
LT has changed over time, the results found on patients who underwent LT ten years ago may 
no longer apply. Second, we included in our models many prognostic factors that have never 
been taken into account in previous studies. For instance, the year of  transplantation 
procedure  is linked to survival and to the likelihood of receiving a bilateral LT (Figure 1); 
and thus may be an important confounding factor. Including such a large number of patients 
gave us the opportunity to adjust on this confounding factor (and many others), whereas 
previous studies could not. Third, we systematically addressed the potential limitations of this 
study by performing sensitivity analyses. Fourth, we applied several methods of adjustment to 
take into account potential selection biases. The fact that all these methods yield similar 
conclusions strengthens the soundness of our results. Previous studies were either not 
powerful enough to adjust for confounding factors or performed only conventional modelling 
approaches.  
Conventional modelling approaches can produce biased estimates if background 
characteristics are extremely unbalanced and/or the effect of surgical procedure is not 
constant across values of background characteristics.28, 29, 32 To circumvent this limitation, we 
used propensity scores, which have been shown to considerably reduce bias. Formally, the 
propensity score for an individual is the probability of being treated (here to receive BLT) 
based on the individual’s covariate values. Practically, the propensity score is estimated by 
logistic regression, whereby the treatment variable is the outcome and the background 
characteristics are the predictor variables. Within propensity-score strata, covariates in both 
groups are similarly distributed.28, 29, 32 The propensity score, once estimated, can be 
incorporated in the analysis either by stratification or by matching on the propensity score. 
Matching on the propensity score consists of matching all treated subjects with one control 
subject within a preset amount (or calliper) of the treated subject’s propensity score. In the 
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present study, we found 3024 pairs of patients sharing close propensity scores. This approach 
was successful in creating pairs of patients with similar background covariates, as shown in 
Table 4. Although propensity scores cannot remove hidden biases, except to the extent that 
unmeasured prognostic variables are correlated with the measured covariates used to compute 
the score, the balance in the distribution of measured risk factors provides reasonable 
evidence to infer that the distribution of unmeasured variables is likely balanced.  
None of these statistical methods can be viewed as the gold standard for removing 
bias, and all have drawbacks. However, in the present study, all methods yielded very similar 
results, which supports the robustness of our findings. Depending on the statistical method 
used, the adjusted hazard ratios ranged from 0.83 to 0.89, which translates to a 4.0% to 6.3% 
better survival at 5 years with BLT than SLT.  
A key issue is whether BLT leads to better long-term survival whatever the recipient 
age, the study by Meyer et al suggesting that SLT could lead to better long-term survival in 
older patients.19 Unfortunately, the answer to this question is not trivial, from a statistical 
standpoint. In our study, the interaction between recipient age and surgical procedure did not 
reach statistical significance (p=0.25). When the population was split into 4 groups according 
to quartiles of age, the benefit of BLT over SLT was restricted to patients younger than 60 
years. However, this result may be explained by the decreased statistical power due to data 
splitting. 
This study has several limitations. First, our analyses involved data with varying levels 
of validation from many countries, and data for some patients may be inaccurate. However, 
misclassification of data should not bias the results in favour of one technique over another 
and seems an unlikely explanation for our findings.  We addressed this limitation by running 
several sensitivity analyses on the United Network for Organ Sharing dataset, in which data 
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for date of death are from the U.S. Social Security Death Master File; the results remained 
largely unchanged.  
Second, we used observational data to study the impact of surgical procedure on long-
term survival. Although we used several statistical approaches to take into account a large 
number of confounders, residual confounding is possible. Only a randomized controlled trial 
(RCT) would definitely answer this question. Taking into account an expected 5% difference 
in 5-year survival, such a trial should enrol and follow more than 3000 patients for 5 years. 
Such a large-scale trial seems unlikely to be performed in the LT field. However, in certain 
respects, our approach produced results that could be more useful than those from a RCT, 
especially in relation to external validity. Most RCTs recruit only a small proportion of the 
patients with the disease of interest, and those recruited are likely to systematically differ 
from those not recruited.  
Third, the mechanisms underlying the better survival following BLT remain unclear 
and could not be investigated from this registry. We were unable to assess the cause of death 
according to procedure because data were too poorly reported in this registry. As others have 
shown, cause of death cannot be reliably determined without the use of an adjudication 
committee.33 
Finally, several important topics  not addressed by the present study remain 
controversial, including: (1) the unclear potential survival benefit conferred by lung 
transplantation over conventional treatment; (2) the respective places of lung volume 
reduction procedures (surgery or endobronchial valves) in the management of patients with 
emphysema; (3) the optimal surgical approaches for sequential bilateral lung transplantation, 
such as  single lung transplantations performed on each side a few years apart; and (4) the 
balance of individual survival benefits versus optimizing ethical organ allocation.  
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In conclusion, the present study strongly supports BLT leading to better survival than 
SLT for COPD patients. However, only a randomised controlled trial would be able to 
definitely confirm this hypothesis. Furthermore, any potential survival benefit must be 
weighed against the potential societal benefits of organ allocation to subjects with advanced 
lung diseases.   
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Figure legends 
Figure 1. Rates of single lung transplantation (SLT) and bilateral lung transplantation 
(BLT) over time.  
All patients with chronic obstructive pulmonary disease (COPD) who underwent lung 
transplantation between 1987 and 2006. 15.4% of patients undergoing SLT had alpha-1 
antitrypsin deficiency versus 27.8% of patients undergoing BLT. 
 
Figure 2. Survival following lung transplantation between 1987 and 2006, according to 
transplantation procedure (single vs. bilateral).  
Panel A shows the survival of the 9883 patients with chronic obstructive pulmonary disease 
(COPD) undergoing transplantation during the study period (single lung transplantation 
[SLT]=6358; bilateral lung transplantation [BLT]=3525). Panel B shows the survival of the 
6048 patients matched by propensity score (SLT=3024, BLT=3024). Survival was by Kaplan-
Meier estimation.  
 
 
Figure 3. Adjusted hazard ratio for death associated with bilateral lung transplantation 
by recipient age at transplantation.  
Four age classes were determined according to quartiles of distribution. Hazard ratios were 
adjusted for recipient age at transplant, New York Heart Association functional class, body 
mass index, ventilator requirement, donor age, donor body mass index, donor diabetes status, 
number of human leucocyte antigen mismatches, cytomegalovirus mismatch and year of 
transplantation. HR, adjusted hazard ratio. 
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Figure 4. Hazard ratio for death associated with bilateral lung transplantation by 
several adjustment methods.  
Hazard ratio < 1 indicates a beneficial effect of bilateral lung transplantation. Unadjusted 
analysis refers to a univariate Cox model. Analysis of covariance refers to a multivariate Cox 
model adjusting for age at transplantation, New York Heart Association functional class, body 
mass index, ventilator requirement, donor age, donor body mass index, donor with diabetes, 
number of human leucocyte antigen mismatches, cytomegalovirus (CMV) mismatch (i.e. 
donor CMV+ and recipient CMV-) and year of transplantation. Propensity decile refers to a 
multivariate Cox model adjusted for propensity-score deciles. Propensity decile + covariates 
refers to a multivariate Cox model adjusted for propensity-score deciles and to the variables 
included in the analysis of covariance. Propensity-based matching refers to a Cox model 
applied to patients matched on the propensity score. HR, adjusted hazard ratio. 
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Table 1. Variables tested for association with survival from lung transplantation. 
Donor-related characteristics 
Age, gender, height, weight, cause of death, history of diabetes, blood group, CMV status, HLA typing 
Surgery-related characteristics 
Single or bilateral LT, graft ischemic time, transplantation year 
Recipient characteristics
Age, gender, height, weight, history of diabetes, blood group, CMV status, HLA typing, prior malignancy, 
ventilatory support, hospitalization within 90 days before transplantation, alpha-1 antitrypsin deficiency, NYHA 
functional class, oxygen requirement, FEV1, FVC, PAPs, PAPm, PAPd, PCWP, CO, panel reactive antibody 
Calculated variables 
Blood group mismatch, CMV mismatch, number of HLA mismatches, gender mismatch, donor and recipient 
body mass index 
FEV1 denotes forced expiratory volume in 1s; CMV, cytomegalovirus; HLA, human leucocyte antigen; LT, lung 
transplantation; FVC, forced vital capacity; NYHA, New York Heart Association; PAPs, systolic pulmonary artery pressure; 
PAPm, mean pulmonary artery pressure; PAPd, diastolic pulmonary artery pressure; PCWP, pulmonary capillary wedge 
pressure; CO, cardiac output. 
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Table 2. Main baseline characteristics of the 9883 patients with COPD according to type 
of lung transplantation. 
 Single LT (n=6358) 
Bilateral LT 
(n=3525) 
Standardized 
difference (%) 
Recipient characteristics    
Age (years)  55.5 (6.8) 52.2 (7.8) 45.2 
Age distribution (%) 
              < 50  
              [50 – 55[  
              [55 – 60[ 
              ≥ 60 
21.4 
23.5 
30.8 
23.4 
38.2 
23.9 
24.1 
13.9 
37.5 
0.8 
15.1 
26.9 
Female (%) 52.8 44.1 17.8 
α-1 anti-trypsin deficiency (%) 15.4 27.8 30.4 
NYHA Class‡ (%)    
              I, II 
              III 
              IV 
27.2 
63.9 
8.9 
26.1 
60.7 
13.2 
2.5 
6.6 
13.8 
Diabetes status (%) 3.1 3.7 3.0 
Oxygen required at rest (%) 85.9 85.6 3.0 
FEV1 (% of predicted) 22.2 (11.7) 21.7 (12.8) 3.7 
FVC (% of predicted) 50.4 (17.4) 50.8 (19.0) 2.1 
PCWP (mmHg) 12.0 (5.5) 12.4 (5.4) 4.7 
PAPs (mmHg) 36.3 (11.0) 36.8 (11.7) 2.6 
Body mass index† 23.4 (6.4) 23.4 (7.4) 3.6 
Donor characteristics    
Age (yr)  32.7 (13.8) 34.4 (14.0) 12.4 
Male (%) 65.8 63.9 4.0 
Body mass index† 24.3 (4.3) 24.4 (4.3) 2.2 
Diabetes (%) 2.7 3.7 5.7 
Cause of death (%)    
          Anoxia 
          Stroke 
          Head trauma 
          Central nervous system tumor 
          Other 
4.3 
30.2 
52.2 
0.9 
12.3 
4.5 
31.6 
52.0 
1.3 
10.6 
0.9 
3.0 
0.5 
3.4 
5.3 
Donor/recipient characteristics    
CMV mismatch (%) 16.7 19.7 7.8 
Gender mismatch (%) 32.5 24.8 17.2 
Blood group mismatch (%) 9.7 9.0 2.4 
Number of HLA mismatches  4.51 (1.13) 4.48 (1.12) 2.5 
* Data are mean (SD) unless otherwise indicated. FEV1 denotes forced expiratory volume in 1 s; FVC, forced vital capacity; 
PCWP, pulmonary capillary wedge pressure; PAPs, systolic pulmonary artery pressure. †Body mass index is weight in 
kilograms divided by the square of the height in meters. ‡ NYHA, New York Heart Association: functional class ranges I to 
IV, with IV indicating that the patient experiences symptoms even at rest. Standardized difference is the mean difference 
divided by the pooled SD, expressed as a percentage.  
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Table 4. Main baseline characteristics of the 6048 patients matched by propensity score 
according to type of lung transplantation. 
 Single LT (n=3024) 
Bilateral LT 
(n=3024) 
Standardized 
difference (%) 
Recipient characteristics     
Age (years)  53.3 (7.2) 53.2 (7.3) 1.5 
Age distribution (%) 
              < 50  
              [50 – 55[  
              [55 – 60[ 
              ≥ 60 
31.2 
26.8 
26.2 
15.8 
32.6 
24.9 
26.4 
16.0 
2.4 
1.3 
2.2 
1.2 
Female (%) 54.2 53.7 1.3 
α-1 anti-trypsin deficiency (%) 23.0 23.8 2.4 
NYHA Class‡ (%)    
                           I, II 
                           III 
                           IV 
26.2 
62.0 
11.9 
25.9 
62.8 
11.3 
0.6 
0.3 
0.4 
Diabetes (%) 3.9 3.4 3.3 
Oxygen required at rest (%) 86.5 86.8 1.0 
FEV1 (% of predicted) 22.1 (12.6) 21.8 (12.5) 0.4 
FVC (% of predicted) 50.9 (18.2) 50.5 (18.5) 1.8 
PAPs (mmHg) 36.7 (11.7) 36.7 (11.3) 0.3 
Body mass index† 23.3 (4.4) 23.2 (4.2) 1.4 
Donor characteristics    
Age (yr)  34.0 (14.4) 34.4 (14.1) 2.0 
Male (%) 64.0 63.6 0.3 
Body mass index† 24.4 (4.3) 24.3 (4.2) 1.2 
Diabetes (%) 3.3 3.4 0.4 
Cause of death (%)    
          Anoxia 
          Stroke 
          Head trauma 
          Central nervous system tumor 
          Other 
4.6 
32.6 
50.4 
1.3 
11.2 
4.6 
31.5 
50.3 
1.1 
12.5 
0 
2.3 
0.2 
1.2 
4.0 
Donor/recipient characteristics    
CMV mismatch (%) 18.9 19.4 1.5 
Gender mismatch (%) 25.6 25.7 0.2 
Blood group mismatch (%) 9.6 9.0 1.3 
Number of HLA mismatch  4.5 (1.1) 4.5 (1.1) 0.7 
* Data are mean (SD) unless otherwise indicated. FEV1 denotes forced expiratory volume in 1 s; FVC, forced vital capacity; 
PCWP, pulmonary capillary wedge pressure; PAPs, systolic pulmonary artery pressure. † Body mass index is the weight in 
kilograms divided by the square of the height in meters. ‡ NYHA, New York Heart Association: functional classes range 
from I to IV, with IV indicating that the patient experiences symptoms even at rest. Standardized difference is the mean 
difference divided by the pooled SD, expressed as a percentage.  
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Online data supplement to: 
Survival after bilateral lung transplantation versus single lung 
transplantation for patients with chronic obstructive pulmonary disease: a 
cohort study.   
 
Gabriel Thabut, Jason D. Christie, Philippe Ravaud, Yves Castier, Olivier Brugière, Michel 
Fournier, Hervé Mal, Guy Lesèche, Raphaël Porcher. 
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This section details the method of multiple imputation that was used to handle missing 
data. 
In this study, we used the multiple-imputation-by-chained equation to handle missing data.1  
Multiple imputation is a Monte Carlo technique in which the missing values are replaced by 
m (m=5 in this study) simulated versions. The missing values are drawn from an appropriate 
distribution that characterizes the conditional relation of the imputed variables to other 
variables. Because the missing values are drawn from a distribution, a range of values will be 
imputed for each missing value, with this variation reflecting the uncertainty about this 
missing value.  
The implementation of multiple imputation in this study is based on the procedure described 
by Raghunatan et al 1 and implemented in R (mice package).  
Briefly, the multiple-imputation-by-chained equation proceeds as follows:  
1. To get started, for each variable in turn, fill in missing values with randomly chosen 
observed values.  
2. “Filled-in” values in the first variable are discarded, leaving the original missing 
values. These missing values are then imputed by regression imputation on all other 
variables.  
3. The “filled-in” values in the second variable are discarded. These missing values are 
then imputed using “proper” regression imputation on all other variables.  
4. This process is repeated for each variable in turn. Once each variable has been 
imputed using the regression method, one “cycle” is completed.  
The process is continued for 10 cycles. 
After imputation, each of the m completed datasets is analysed separately, and the results are 
combined 2,3 by use of the following formulas:  
We define the following parameters:  
m: the number of sets imputed and analyzed 
iβˆ  : point estimate from analyzing the ith set 
iνˆ : variance estimate from analyzing the ith set 
β : combined estimate of β 
ν : combined estimate of v 
β  = ∑
=
m
i
im 1
ˆ1 β  
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The within-imputation variance is calculated as follows:  
withinν  = ∑
=
m
i
im 1
ˆ1 ν  
The between-imputation variance is calculated as follows:  
 betweenν  = 2
1
)ˆ(
1
1 ββ −− ∑=
m
i
im
 
The total variance is:  
 totalν  =  betweenwithin m νν ⎟⎠
⎞⎜⎝
⎛ ++ 11  
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